John/Richard:
I'm holding long-term. I usually use a combo of trading and core-holding for most issues that I really believe in. However, due to the capitalization at which MLNM went public, I've never tried the trading side of their equation (apart from some calls, one correct guess last month, one bad guess last Fall). That is, I prefer small cap biotechs for trading.
This is one of my "put it in the closet and look at it in five years" biotechs.
Obligatory meat..... pharmacogenomics......... this field is looking, to me, like it's going to actually unfold to be as hot as the hype. But..... will "we" be extending the ethical window that is already taxed by genetic susceptibility testing? That is, will a person's genetic "weakness" fingerprint be extended to cover not only disease potential but also to a relative inability to thrive in a world of rapid deployment genes/pharmachems? Will Rifkin et al. see a world, thirty years off, where babies are discarded due to a bad p450 profile?
I sort of look at this as the next step after "chiral" companies. First, "we" got rid of the complexity in the chemical. Next, we get rid of the complexity in the patient. Is anyone else looking forward to the intersection, when it really gets rolling, of pharmacogenomics and neurochemistry?
The next twenty years are going to be interesting if not exciting. Humans are going to be increasingly divided into the chemical "haves" and "have nots", and we're already firmly immersed in cosmetic (e.g., baldness) chemistry. Will the combination of genomics and pharmacogenomics lead us, eventually, to consider the prophylaxis of ugliness as ethical?
Rick |
